Hereditary Cancer Screen
A 48-gene screening test for hereditary cancer predisposition across breast, gynecologic, prostate, and gastrointestinal systems, powered by the Helix Exome+® platform.
6-21 days
≤ 5 days
Panel Description
Helix Hereditary Cancer Screen is a screening test that analyzes 48 genes associated with hereditary cancer conditions that predispose to a variety of primarily adult-onset solid tumors across many organ systems including: breast, gynecologic (ovarian and uterine), prostate, and those in the gastrointestinal system. This test only reports clinically significant pathogenic and likely pathogenic variants but does not report variants of uncertain significance (VUS).
Have Questions?
Our team is available Monday through Friday, 9am-5pm Pacific Time.
Indications for Testing
This is a screening test and therefore is not recommended for individuals with a personal and/or family history suggestive of one of the associated conditions. Early detection and/or intervention for the conditions tested here could significantly reduce morbidity and mortality.
Methodology
This test utilizes next-generation sequencing to detect single nucleotide variants, insertions and deletions up to 20 bp, and copy number variants in genes associated with hereditary conditions predisposing to cancers including: breast, gynecologic (ovarian and uterine), prostate, and those in the gastrointestinal system.
Technical Specifications
> 99%
> 99%
> 99%
> 99%
> 90%
APC: analysis includes CNV of promoters 1A and 1B and sequencing of promoter 1B; BMPR1A: analysis includes CNV of promoter; BRCA1: sequencing analysis extends to CDS +/-20 bp; BRCA2: analysis includes...
GRCh38
Genes Tested
Showing 25 of 48 genes in this panel